Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Lilly's already holding its own in immunology with Taltz, which made nearly $3.3 billion in sales last year. Omvoh could carve a niche for itself in the Crohn's disease market. Ebglyss should also ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly announced an expansion of its LillyDirect digital healthcare platform to facilitate contact with healthcare providers for Alzheimer's patients—providing a targeted solution for timely ...

Eli Lilly and Company discovers ... and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized ...